구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tecartus |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.. BackgroundTecartus (brexucabtagene autoleucel) is an autologous CAR-T product targeting CD19, but there are many undetected and unreported adverse events (AEs).MethodsWe counted data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from … |
Toxicology CRS | Reported |
Clinical Safety signal | Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.. BackgroundTecartus (brexucabtagene autoleucel) is an autologous CAR-T product targeting CD19, but there are many undetected and unreported adverse events (AEs).MethodsWe counted data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from … |
Clinical Selected reported efficacy | ORR 86% |
Clinical Reported ORR | 86% |
Clinical Result source | ClinicalTrials.gov NCT02601313 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02601313 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tecartus |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.. BackgroundTecartus (brexucabtagene autoleucel) is an autologous CAR-T product targeting CD19, but there are many undetected and unreported adverse events (AEs).MethodsWe counted data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from … |
Toxicology CRS | Reported |
Clinical Safety signal | Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.. BackgroundTecartus (brexucabtagene autoleucel) is an autologous CAR-T product targeting CD19, but there are many undetected and unreported adverse events (AEs).MethodsWe counted data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from … |
Clinical Selected reported efficacy | ORR 86% |
Clinical Reported ORR | 86% |
Clinical Result source | ClinicalTrials.gov NCT02601313 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02601313 |
추천 비교
추천 비교